SCHEMBL17352471

SCHEMBL17352471

NC(CS)C(=O)N1CCC1C(=O)NC(CS)C(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 3/20 0.39
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
ALOX15 P16050 2/20 0.38
PTGS2 P35354 2/20 0.38
THPO P40225 2/20 0.38
THRB P10828 1/20 0.38
NFKB1 P19838 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
GRB2 P62993 1/20 0.37
XIAP P98170 1/20 0.36
NRP1 O14786 1/20 0.36
ACE P12821 4/20 0.36
FNTA P49354 2/20 0.36
FNTB P49356 2/20 0.36
F2 P00734 1/20 0.36
REN P00797 1/20 0.36
LMNA P02545 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29366371 0.92 OPRM1 (0.46) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL17352470 0.92 OPRM1 (0.46) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL17352458 0.91 OPRM1 (0.43) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL29355564 0.88 GRB2 (0.47) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL17352464 0.86 OPRM1 (0.40) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL31065472 0.85 OPRM1 (0.45) OPRM1GRB2F2
SCHEMBL29374739 0.85 OPRM1 (0.45) OPRM1GRB2F2
SCHEMBL29776753 0.85 OPRM1 (0.48) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL29886469 0.85 OPRM1 (0.46) OPRM1KDM4EMAPTALOX15PTGS2
SCHEMBL29363345 0.84 OPRM1 (0.46) OPRM1GRB2XIAPF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170095445-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG RADIKAL THERAPEUTICS INC (US) 2017-04-06 US disclosed
US-20170095445-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG RADIKAL THERAPEUTICS INC (US) 2017-04-06 US disclosed
US-20170095445-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG RADIKAL THERAPEUTICS INC (US) 2017-04-06 US disclosed
US-20150368197-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG RADIKAL THERAPEUTICS INC. 2015-12-24 US disclosed
US-20150368197-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG RADIKAL THERAPEUTICS INC. 2015-12-24 US disclosed
US-20150368197-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG RADIKAL THERAPEUTICS INC. 2015-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150368197-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG ELANE, CYSLTR1, CYSLTR2 OPRM1 2940/4885KDM4E 4780/4885MAPT 4002/4885
US-20170095445-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATORY DISEASES OF THE LUNG MPO, ELANE, CYSLTR2 OPRM1 2977/4885KDM4E 4764/4885MAPT 4281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.